This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



dolutegravir/lamivudine (Dovato®)


Reference No. 3659

Publication date:
18/02/2020


Appraisal information

dolutegravir/lamivudine (Dovato®) 50 mg/300 mg film-coated tablet


Company: ViiV Healthcare UK Ltd
BNF category: Infections
NMG meeting date: 08/01/2020
AWMSG meeting date: 11/02/2020
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0220
Ratification by Welsh Government: 14/02/2020

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Dolutegravir/lamivudine (Dovato®) is recommended as an option for use within NHS Wales for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download